Skip to main content
. 2019 Jul 16;11(8):e10058. doi: 10.15252/emmm.201810058

Figure 7. Tumor‐related processes are affected by IBL‐302 treatment.

Figure 7

LU‐NB‐3 PDX cells were treated with 50 nM of IBL‐302 for 48 h and subsequently analyzed by RNAseq and mass spectrometry.
  • A–C
    Heat map of significantly differentially expressed genes across treatment groups from RNAseq data (FDR < 0.1) (A). Genes defined as differentially expressed that were also present in MS and phospho‐MS are visualized in (B) and (C), respectively.
  • D
    Gene ontology generated from significantly altered genes from RNAseq data. −log(P‐values) and percent of input gene/protein lists that overlap with the specified ontology are displayed.
  • E
    Gene ontology generated from significantly altered proteins from mass spectrometry proteome data. −log(P‐values) and percent of input gene/protein lists that overlap with the specified ontology are displayed.
  • F
    Gene ontology generated from significantly altered phospho‐proteins from mass spectrometry phospho‐proteome data. −log(P‐values) and percent of input gene/protein lists that overlap with the specified ontology are displayed.
  • G
    Cross‐platform sample correlations of RNAseq and mass spectrometry proteome data. Pearson's correlation coefficients are displayed.